A share price of Monopar Therapeutics Inc [MNPR] is currently trading at $24.46, down -2.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MNPR shares have gain 11.18% over the last week, with a monthly amount glided 13.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on October 11, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $50. Previously, ROTH Capital started tracking the stock with Buy rating on January 28, 2021, and set its price target to $49.
Monopar Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.54 and $38.50. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $24.46 at the most recent close of the market. An investor can expect a potential return of 20.61% based on the average MNPR price forecast.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -215.74, Equity is -217.32 and Total Capital is -1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.88 points at the first support level, and at 23.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.02, and for the 2nd resistance point, it is at 25.58.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Monopar Therapeutics Inc [NASDAQ:MNPR] is 5.41. As well, the Quick Ratio is 5.41, while the Cash Ratio is 5.36.
Transactions by insiders
Recent insider trading involved Radhakrishnan Karthik, Chief Financial Officer, that happened on Oct 28 ’24 when 1550.0 shares were purchased. Chief Operating Officer, Cittadine Andrew completed a deal on Jun 20 ’24 to buy 20508.0 shares. Meanwhile, Chief Operating Officer Cittadine Andrew bought 12000.0 shares on Jun 18 ’24.
